No Data
No Data
Monthly Information on Share Capital and Company Voting Rights
Cellectis S.A. Updates UCART Pipeline With Phase 2 Trial Details
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
JMP Securities Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $6
Cellectis Reports 2024 Financial Results and Strategic Advances
Cellectis | 20-F/A: Registration statement / Annual report / Transition report (Amendment)